Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3901931 | 1.00 | CYP2D6 (0.56) | CYP2D6CYP2C9CYP2C19NPSR1GRIN2D | |
| SCHEMBL26362107 | 0.85 | NPSR1 (0.47) | CYP2D6CYP2C9CYP2C19NPSR1HCAR2 | |
| SCHEMBL19968924 | 0.85 | NPSR1 (0.47) | CYP2D6CYP2C9CYP2C19NPSR1HCAR2 | |
| SCHEMBL15480725 | 0.85 | NPSR1 (0.47) | CYP2D6CYP2C9CYP2C19NPSR1HCAR2 | |
| SCHEMBL6279268 | 0.83 | NPSR1 (0.46) | CYP2D6CYP2C9CYP2C19NPSR1HCAR2 | |
| SCHEMBL6281310 | 0.83 | NPSR1 (0.46) | CYP2D6CYP2C9CYP2C19NPSR1HCAR2 | |
| SCHEMBL2079724 | 0.81 | NPSR1 (0.44) | CYP2D6CYP2C9CYP2C19NPSR1HCAR2 | |
| SCHEMBL711893 | 0.81 | NPSR1 (0.44) | CYP2D6CYP2C9CYP2C19NPSR1HCAR2 | |
| SCHEMBL11091894 | 0.81 | CYP2D6 (0.46) | CYP2D6CYP2C9CYP2C19NPSR1GRIN2D | |
| SCHEMBL11091892 | 0.81 | CYP2D6 (0.46) | CYP2D6CYP2C9CYP2C19NPSR1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488854-B2 | (11E,13E)-labda-11,13-diene-8'',15-diol abdan-type diterpene derivatives; plants protection from various stresses, such as injury, insect pests, disease, and hypersensitivity cell death | THE NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES (JP) | 2009-02-10 | — | — | US | disclosed |
| US-20060003896-A1 | (11E,13E)-labda-11,13-diene-8'',15-diol abdan-type diterpene derivatives; plants protection from various stresses, such as injury, insect pests, disease, and hypersensitivity cell death | NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES | 2006-01-05 | — | — | US | disclosed |
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| US-6465646-B1 | 1-alkoxy and 1-acyloxy substituted cyclohex-1-ene compounds and sulfur and 1-alkoxycarbonyl analogs having retinoid-like biological activity | ALLERGAN, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6403638-B1 | COMPOUND FOR USE IN TREATING SKIN DISEASES AND DISORDERS, AND FOR TREATING HYPERVITAMINOSIS A SYNDROME | ALLERGAN SALES, INC. | 2002-06-11 | — | — | US | disclosed |
| WO-2001070662-A2 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN , INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6177588-B1 | HAVING RETINOID-LIKE, RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST-LIKE BIOACTIVITY; SIDE EFFECT REDUCTION; SKIN DISORDERS; ANTIPROLIFERATIVE AND -CARCINOGENIC AGENTS; MICROBIOCIDES; VISION DEFECTS; CARDIOVASCULAR DISORDERS | ALLERGAN SALES, INC. | 2001-01-23 | — | — | US | disclosed |
| WO-2000068190-A2 | 1-ALKOXY AND 1-ACYLOXY SUBSTITUTED CYCLOHEX-1-ENE COMPOUNDS AND SULFUR AND 1-ALKOXYCARBONYL ANALOGS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000026173-A1 | NOVEL RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (DE) | 2000-05-11 | — | — | WO | disclosed |
| EP-0975573-A1 | TRISUBSTITUTED PHENYL DERIVATIVES HAVING RETINOID AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | Allergan Sales, Inc. (US) | 2000-02-02 | — | — | EP | disclosed |
| US-6005007-A | SKIN DISORDERS | LIGAND PHARMACEUTICALS INCORPORATED | 1999-12-21 | — | — | US | disclosed |
| EP-0937045-A1 | N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY | Allergan Sales, Inc. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998047854-A1 | TRISUBSTITUTED PHENYL DERIVATIVES HAVING RETINOID AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998019999-A1 | N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY | ALLERGAN SALES, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| WO-1997012853-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |
| US-4439614-A | INHIBITING TUMOR PRODUCTION IN SKIN | SRI INTERNATIONAL (US) | 1984-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | CYP2D6 754/4885CYP2C9 757/4885CYP2C19 1159/4885 |
| US-20060003896-A1 | (11E,13E)-labda-11,13-diene-8'',15-diol abdan-type diterpene derivatives; plants protection from various stresses, such as injury, insect pests, disease, and hypersensitivity cell death | DRD1, ALOX15, ALOX12 | CYP2D6 687/4885CYP2C9 976/4885CYP2C19 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.